ERBB2 and neoplasm: By contrast, tumours with higher levels of ERBB2 and lower associated immunity had a significantly higher risk of relapse, indicating that these patients may benefit from an intensified anti-HER2 treatment, using for example double anti-HER2 blockade or adjuvant TDM1.27